drug

DMXB-A-SR

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by University of Colorado, Denver
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
Nicotinic Receptors and Schizophrenia
NCT01400477Phase 2Completed

KOLs & investigators

1
Robert Freedman, MDKOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
University of Colorado, Denver
company
trial
Nicotinic Receptors and Schizophrenia
PHASE2
trial
indication
Schizophrenia
indication
Smoking Cessation
indication
Schizophrenia
indication
Psychotic Disorders
indication
KOL
Robert Freedman, MD
KOL score 5
person